C. Hoffer

发表

Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites

E. Kharasch, D. Shen, L. Risler, 2006, Clinical pharmacology and therapeutics.

harmacokinetics and pharmacodynamics f oral oxycodone in healthy human ubjects : Role of circulating active etabolites

E. Kharasch, L. Risler, Bojan Lalovic, 2006 .

Simultaneous Measurement of In Vivo P‐glycoprotein and Cytochrome P450 3A Activities

E. Kharasch, J. Unadkat, B. Kirby, 2006, Journal of clinical pharmacology.

Influence of Hepatic and Intestinal Cytochrome P4503A Activity on the Acute Disposition and Effects of Oral Transmucosal Fentanyl Citrate

E. Kharasch, D. Whittington, C. Hoffer, 2004, Anesthesiology.

Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

E. Kharasch, D. Whittington, N. Isoherranen, 2007, Clinical pharmacology and therapeutics.

Role of P‐glycoprotein in the intestinal absorption and clinical effects of morphine

E. Kharasch, D. Whittington, P. Sheffels, 2003, Clinical pharmacology and therapeutics.

Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and Pharmacodynamics

D. Whittington, E. Kharasch, S. Campbell, 2012, Clinical pharmacology and therapeutics.

Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport: Insights from Methadone Interactions with Ritonavir/Indinavir

E. Kharasch, D. Whittington, C. Hoffer, 2009, Anesthesiology.

The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.

E. Kharasch, D. Whittington, C. Hoffer, 2004, British journal of clinical pharmacology.

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate

E. Kharasch, D. Whittington, C. Hoffer, 2004, Anesthesiology.

Quinidine as a Probe for the Role of P‐Glycoprotein in the Intestinal Absorption and Clinical Effects of Fentanyl

E. Kharasch, D. Whittington, C. Hoffer, 2004, Journal of clinical pharmacology.

Disposition of nasal, intravenous, and oral methadone in healthy volunteers

E. Kharasch, O. Dale, P. Sheffels, 2002, Clinical pharmacology and therapeutics.

Paradoxical Role of Cytochrome P450 3A in the Bioactivation and Clinical Effects of Levo-α-Acetylmethadol

P. Vicini, E. Kharasch, D. Whittington, 2005 .

KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A Feasibility Study

M. Jensen, D. Patterson, S. Sharar, 2018, The International journal of clinical and experimental hypnosis.

Sensitivity of Intravenous and Oral Alfentanil and Pupillary Miosis as Minimally Invasive and Noninvasive Probes for Hepatic and First‐Pass CYP3A Activity

E. Kharasch, P. Sheffels, C. Hoffer, 2005, Journal of clinical pharmacology.

Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In Vivo

W. L. Nelson, E. Kharasch, N. Isoherranen, 2008, Clinical pharmacology and therapeutics.

Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.

E. Kharasch, D. Whittington, C. Hoffer, 2009, Drug and alcohol dependence.

Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone

E. Kharasch, D. Whittington, P. Sheffels, 2004, Clinical pharmacology and therapeutics.

Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A)

E. Kharasch, D. Whittington, C. Hoffer, 2012, Anesthesiology.

Intravenous and oral alfentanil as in vivo probes for hepatic and first‐pass cytochrome P450 3A activity: Noninvasive assessment by use of pupillary miosis

E. Kharasch, P. Sheffels, C. Hoffer, 2004, Clinical pharmacology and therapeutics.

Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: I. Evidence Against CYP3A Mediation of Methadone Clearance

D. Whittington, E. Kharasch, C. Hoffer, 2008, Clinical pharmacology and therapeutics.

Mechanism of Ritonavir Changes in Methadone Pharmacokinetics and Pharmacodynamics: II. Ritonavir Effects on CYP3A and P‐Glycoprotein Activities

D. Whittington, E. Kharasch, C. Hoffer, 2008, Clinical pharmacology and therapeutics.

Circumplex Model of Affect: A Measure of Pleasure and Arousal During Virtual Reality Distraction Analgesia.

Hunter G Hoffman, M. Jensen, H. Hoffman, 2016, Games for health journal.

Evaluation of First‐Pass Cytochrome P4503A (CYP3A) and P‐Glycoprotein Activities Using Alfentanil and Fexofenadine in Combination

Evan D Kharasch, E. Kharasch, Christine Hoffer, 2005, Journal of clinical pharmacology.

Sensitivity of intravenous and oral alfentanil miosis as a noninvasive probe for hepatic and first‐pass CYP3A activity

E. Kharasch, C. Hoffer, A. Walker, 2004 .

Influence of Age on the Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Fentanyl Citrate

E. Kharasch, D. Whittington, C. Hoffer, 2004, Anesthesiology.

Disposition and miotic effects of oral alfentanil: A potential noninvasive probe for first‐pass cytochrome P4503A activity

E. Kharasch, P. Sheffels, C. Hoffer, 2003, Clinical pharmacology and therapeutics.

Methadone Pharmacokinetics Are Independent of Cytochrome P4503A (CYP3A) Activity and Gastrointestinal Drug Transport: Insights from Methadone Interactions with Ritonavir/Indinavir

E. Kharasch, D. Whittington, C. Hoffer, 2009, Anesthesiology.